-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Exagen, Lowers Price Target to $9

Benzinga·03/10/2026 18:54:22
Listen to the news
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $10 to $9.